AstraZeneca names new Head of Investor Relations

AstraZeneca PLC reports a leadership change in its investor relations function.

Rhea-AI Filing Summary

AstraZeneca PLC reports a leadership change in its investor relations function. The company has appointed Joris Silon as Head of Investor Relations, effective 1 March 2026, succeeding Andy Barnett. Joris moves into this role from his position as country president of AstraZeneca US, where he led and delivered significant growth in the company’s largest market, and he will be based in Cambridge, UK. He brings extensive pharmaceutical experience, having joined AstraZeneca in 2000 and held leadership roles across Asia, Europe and the US. Chief Financial Officer Aradhana Sarin highlighted his experience and thanked Andy Barnett for his leadership of the Investor Relations team over the past four years as he transitions to a new role within the company.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AstraZeneca (AZN) announce in this Form 6-K?

AstraZeneca announced the appointment of Joris Silon as its new Head of Investor Relations, succeeding Andy Barnett, effective 1 March 2026.

Who is AstraZeneca’s new Head of Investor Relations and when does he start?

Joris Silon has been appointed as AstraZeneca’s new Head of Investor Relations. He will assume the role on 1 March 2026 and will be based in Cambridge, UK.

What was Joris Silon’s previous role at AstraZeneca (AZN)?

Before this appointment, Joris Silon served as the country president of AstraZeneca US, where he led and delivered significant growth in the company’s largest market.

Who is Joris Silon replacing as Head of Investor Relations at AstraZeneca?

Joris Silon is succeeding Andy Barnett as AstraZeneca’s Head of Investor Relations. Andy Barnett is moving to an important new role within the company.

What experience does Joris Silon bring to AstraZeneca’s Investor Relations role?

Joris Silon joined AstraZeneca in 2000 and has held leadership positions across Asia, Europe and the US, giving him extensive pharmaceutical and international management experience.

Who commented on the appointment of Joris Silon at AstraZeneca (AZN)?

Aradhana Sarin, AstraZeneca’s Chief Financial Officer, praised Joris Silon as a highly experienced and talented leader and thanked Andy Barnett for his leadership of the Investor Relations team over the past four years.

What does AstraZeneca (AZN) focus on as a biopharmaceutical company?

AstraZeneca is a global, science-led biopharmaceutical company focused on prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/08/2026 - 06:04 AM EST Learn about SEC filing dates

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of January 2026 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.   AZN new Head of Investor Relations Joris Silon

8 January 2026

AstraZeneca appoints Joris Silon as Head of Investor Relations 

AstraZeneca's new head of Investor Relations, Joris Silon, succeeds Andy Barnett on 1 March 2026, and will be based in Cambridge, UK.

Joris is moving from his role as the country president of AstraZeneca US where he led and delivered significant growth for the Company in its largest market. Joris brings extensive pharmaceutical experience, having joined the Company in 2000 and has held leadership positions in Asia, Europe and the US.

Aradhana Sarin, Chief Financial Officer, said "I am delighted that such a highly experienced and talented leader as Joris will lead our Investor Relations team through our next wave of growth. I would also like to thank Andy Barnett for his remarkable leadership of our Investor Relations team over the past 4 years and wish him the best of luck as he transitions to an important new role within the Company."

Notes

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 08 January 2026

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary